Analytical Data
-
Gene name
Coagulation Factor IX/F9
- Application
-
Alternative Names
HEMB; FIX; GLA Domain; PTC; Anti Hemophilic Factor B; Christmas Factor; Plasma Thromboplastic Component; Christmas Disease; Hemophilia B
-
Species
Rabbit
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
G1U9U2
-
Expression Region
IIe228~Lys460
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Coagulation Factor IX (F9) is a crucial protein in the blood coagulation cascade, playing a pivotal role in the intrinsic pathway of coagulation. Its deficiency leads to Hemophilia B, a genetic disorder characterized by prolonged bleeding, spontaneous bleeding episodes, and increased risk of surgical complications. Traditional treatment for Hemophilia B involved infusions of plasma-derived factor IX, which, while effective, carries risks of viral transmission and allergic reactions. The advent of recombinant DNA technology has enabled the production of recombinant Factor IX, offering a safer and more effective alternative. Research in this area focuses on enhancing the efficacy and safety profiles of recombinant F9 through various approaches, such as optimizing its biochemical properties, prolonging its half-life in the circulation, and creating gene therapies that aim to provide long-term expression of the factor in patients. Recent studies have also explored modified variants of recombinant F9 that exhibit improved therapeutic outcomes, paving the way for innovative treatments. As our understanding of the molecular mechanisms underlying coagulation continues to evolve, recombinant Factor IX stands out as a significant advancement in the management of Hemophilia B, potentially transforming the quality of life for affected individuals.
